Preclinical assessment of protective role of anti-androgens in reducing RT-induced bladder toxicity
OC-0098
Abstract
Preclinical assessment of protective role of anti-androgens in reducing RT-induced bladder toxicity
Authors: Riccardo Vago1,2, Stefania Zuppone3, Giorgia Colciago3, Giuseppe Fallara4, Andrea Gebbia5, Nadia Di Muzio6, Antonello Spinelli7, Claudio Fiorino5, Cesare Cozzarini6
1 IRCCS San Raffaele Scientific Institute, Urological Research Institute - Division of Experimental Oncology, Milan, Italy; 2IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy; 3IRCCS San Raffaele Scientific Institute, Urological Research Institute - Division of Experimental Oncology, Milan, Italy; 4IRCCS San Raffaele Scientific Institute, Urology, Milan, Italy; 5IRCCS San Raffaele Scientific Institute, Medical Physics, Milan, Italy; 6IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy; 7IRCCS San Raffaele Scientific Institute, Experimental Imaging Centre, Milan, Italy
Show Affiliations
Hide Affiliations
Purpose or Objective
Radiation-induced cystitis (RC) may arise when pelvic
tumors, such as prostate cancer, are treated with radiotherapy (RT). The
modeling of RT-induced urinary toxicity represents a complex topic, which is
attracting increasing interest in radiotherapy. A thorough understanding of the
mechanisms underlying RC is still largely lacking, and in vivo preclinical research has a decisive role in improving the knowledge
concerning the causes and, hence, the possible solutions in order to at least
limit its clinical impact.
To resemble this condition, we set up a rat animal model, which
allowed us to follow the radiation-cystitis development over time.
Material and Methods
We employed a range of techniques to monitor the RC cystitis,
i.e. ultrasound imaging system, used to measure the bladder wall thickness,
cystometry, to assess the bladder compliance and immunohistochemistry (IHC) to
investigate structural alteration, vascularization and fibrosis. The
anti-androgen Degarelix was used to mitigate the inflammatory radiation effect
since experimental models previously developed at our Institute had highlighted
both the anti-inflammatory and antifibrotic effects of an antiandrogen in a rat
model of bladder damage.
Results
Radiation induced bladder wall thickness increased over time
and it was especially relevant after high doses RT (Figure 1) in the range of 35-40 Gy
(single fraction). We then evaluated the RT-induced functional impairment of
bladder compliance by monitoring the urodynamic parameters (Figure 2): at late time points
(6-8 months), when fibrosis developed and the bladder capacity was reduced, a progressive
reduction of micturition volume and a parallel increase of micturition events
over time after RT were observed. In addition, preliminary structural assessment
performed to confirm the observed functional impairment, revealed an increased
vascularization (increased amount of CD31 positive
vessels) and
fibrosis (increased collagen I deposition). The Degarelix pretreatment prevented
both the radiation-induced impairment of urodynamic
parameters and structural alteration. Specifically, it increased the mean
volume voided per micturition, the micturition interval and reduced the
frequency, when compared to the same parameters observed in the RT-only treated
animals. Moreover, it counteracted the neovascularization and the fibrosis
processes.
Conclusion
Overall our data demonstrated that it is possible to set up
and optimize a rat model of RC, resembling the disease in human beings, which
allows to monitor its onset and development. The pretreatment of the animals
with Degarelix thwarted the radiation-induced functional and structural
alteration of the bladder, highlighting the potential of this approach to be
exported to patients.
Figure 1
Figure 2